WallStSmart
RGNX

Regenxbio Inc

NASDAQ: RGNX · HEALTHCARE · BIOTECHNOLOGY

$8.97
+6.79% today

Updated 2026-04-30

Market cap
$452.17M
P/E ratio
P/S ratio
2.65x
EPS (TTM)
$-3.76
Dividend yield
52W range
$7 – $16
Volume
0.8M

Regenxbio Inc (RGNX) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
-48.8%
Last 4 quarters
Revenue YoY growth
+43.0%
Most recent quarter
EPS YoY growth
-28.7%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-4.4%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-5.4%
2026-03-05
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-05$-1.30-80.7%$9.14$8.65-5.4%
2025-11-06$-1.20+7.7%$11.61$11.21-3.4%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.72$-1.30-80.7%$30.34M+43.0%
2025-09-30$-1.30$-1.20+7.7%$29.73M+22.9%
2025-06-30$-0.94$-1.38-46.8%$21.36M-4.2%
2025-03-31$0.49$0.12-75.3%$89.01M+469.8%
2024-12-31$-1.08$-1.01+6.9%$21.21M-4.5%
2024-09-30$-1.12$-1.17-4.5%$24.20M-16.3%
2024-06-30$-1.29$-1.05+18.6%$22.30M+11.6%
2024-03-31$-1.26$-1.33-5.6%$15.62M-18.4%
2023-12-31$-1.27$-1.43-12.6%$22.21M
2023-09-30$-1.52$-1.41+7.2%$28.91M
2023-06-30$-1.38$-1.66-20.3%$19.98M
2023-03-31$-1.54$-1.53+0.6%$19.14M

Frequently asked questions

Has Regenxbio Inc beaten earnings estimates?
Regenxbio Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of -48.8% over the last 4 quarters.
How does RGNX stock react to earnings?
RGNX stock has moved an average of -4.4% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Regenxbio Inc's revenue growth rate?
Regenxbio Inc reported year-over-year revenue growth of +43.0% in its most recent quarter, with EPS growing -28.7% year-over-year.